(PharmaNewsWire.Com, April 23, 2018 ) Recently, the Swiss Agency for Therapeutic Products granted the orphan drug designation to Aplidin (plitidepsin) for treating multiple myeloma. The orphan drug status enables the drug providers to get additional motivation in terms of marketing, intellectual property, and R&D. Publisher’s market study identifies the advantages of special drug designations to be one of the primary growth factors for the marine pharmaceuticals market. This special orphan drug designation provides several benefits to the drug developers such as 50% tax credit on the cost of clinical trials undertaken in the US. Also, the developer can acquire marketing exclusivity for seven years after the marketing approval. These numerous benefits availed after special drug designations boost the growth of the marine drugs market. Our market analysts estimate that the market will grow steadily at a CAGR of greater than 7% by 2022.
Covered in this report The report covers the present scenario and the growth prospects of the global marine pharmaceuticals market. To calculate the market size, the report considers the revenue generated from the sales of oncology drugs primarily along with cardiovascular, anti-infectives, and others.
The market is divided into the following segments based on geography: - Americas - APAC - EMEA
Publisher's report, global marine pharmaceuticals market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Market driver - Special drug designations - For a full, detailed list, view our report
Market challenge - Regular supply of marine organisms and compounds - For a full, detailed list, view our report
Market trend - Marine peptides as anti-infectives - For a full, detailed list, view our report
Table of Contents
PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE PART 05: MARKET SIZING PART 06: FIVE FORCES ANALYSIS PART 07: MARKET SEGMENTATION PART 08: CUSTOMER LANDSCAPE PART 09: REGIONAL LANDSCAPE PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES PART 12: MARKET TRENDS PART 13: VENDOR LANDSCAPE PART 14: VENDOR ANALYSIS PART 15: APPENDIX
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
